Biopharmaceutical firm Cell Therapeutics Inc. (NASDAQ: CTIC) announced a secondary offering this morning of 60,000 shares of its Series 17 preferred stock at a price of $1,000.00 per share:
Each share of Series 17 Preferred Stock is convertible at the option of the holder, at any time, into approximately 714 shares of common stock at a conversion price of $1.40 per share of common stock, for a total of approximately 42.9 million shares of common stock.
The offering is being underwritten by Jefferies & Company Inc.
According to the announcement, the proceeds to Cell Therapeutics are expected to total $55.6 million and the company plans to use the funds to support the launch of its anticancer pixantrone drug in Europe and to begin phase III trials of another cancer drug, pacritinib.
Shareholders have driven the stock price into the ground this morning. Shares closed at $2.04 last night and are trading in the premarket this morning at $1.46, down 28%. The current 52-week range is $1.77 to $8.25.
Paul Ausick
Find a Qualified Financial Advisor (Sponsor)
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
